Don’t Leave the Highly Prevalent Chronic Diseases Behind

There is a lot to be excited about in biotech right now as we are coming off the heels of a near record year for new drug approvals and many exciting, first in class breakthrough products making their way to patients.
Taking a closer look at these transformative therapies in last year’s FDA approval list reveals numerous biologics indicated for cancer and rare diseases. Among the CBER Biologic Licensing Application (BLA) approvals, we find the 1st gene therapy approved in th